01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development; Providing information about pharmaceutical research and development Medical information; pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Vaccines; vaccines for human use; flu vaccines Scientific research in the nature of conducting clinical trials for pharmaceutical preparations; scientific research in the nature of conducting clinical trials for flu vaccines; providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; Biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; Biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; Lipid nanoparticles for scientific, laboratory or medical research use Vaccine adjuvants; Drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Vaccines; vaccines for human use; flu vaccines Scientific research in the nature of conducting clinical trials in the field of pharmaceutical preparations; conducting clinical trials in the field of flu vaccines; scientific research in the nature of providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development; Providing information about pharmaceutical research and development Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; and medical information, none of the foregoing for optician services, providing information relating to glasses, providing information relating to sunglasses, providing information relating to contact lenses, advisory and consultancy services and information relating to fitting of contact lenses, or vision correction and eye treatment
The present disclosure relates to the field of modified viruses and viral proteins. More particularly, this disclosure relates to modified haemagglutinin proteins, influenza viruses expressing such proteins and methods of making same
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development; Providing information about pharmaceutical research and development Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; and medical information
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
24.
RNA ENCODING VIRUS-LIKE PARTICLES AND USES THEREOF
The present disclosure relates to a composition comprising one or more ribonucleic acids (RNAs) encoding virus-like particle (VLP) forming elements of an influenza virus. The present disclosure further provides uses of the composition.
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing educational information and medical information about immunology, Primary Immunodeficiency and Immunoglobulin G, as well as educational materials distributed in connection therewith
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
The present disclosure provides a method for quantifying a target protein in a sample making use of differentially isotopically labeled variants of the target protein.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/60 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées faisant intervenir des substances marquées radioactives
G01N 27/623 - Spectrométrie de mobilité ionique combinée à la spectrométrie de masse
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
39.
METHODS AND REAGENTS FOR TREATING OR PREVENTING EBV
The present disclosure relates to Epstein-Barr Virus (EBV) (human herpesvirus 4) antigens. Specifically, proteins and uses thereof, and self-amplifying mRNA (sa-mRNA) encoding an EBV antigen and uses thereof. The present disclosure relates to vaccines and therapeutic agents, and production and uses thereof.
Novel ionizable lipid compounds of Formula I or Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61K 9/1272 - Liposomes non conventionnels, p. ex. liposomes modifiés par un PEG ou liposomes enduits de ou greffés avec des polymères comprenant des agents tensioactifs non phosphatidyliques comme substances formant des bicouches, p. ex. lipides cationiques ou liposomes non phosphatidyliques enduits de ou greffés avec des polymères
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
C07C 211/08 - Monoamines contenant des groupes alkyle ayant un nombre différent d'atomes de carbone
C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
C07D 223/04 - Composés hétérocycliques contenant des cycles à sept chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène, des atomes d'halogènes, des radicaux hydrocarbonés ou hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
The present disclosure relates to the field of methods for culturing virally-infected cells. More particularly, this disclosure relates to methods of culturing cells with an influenza A virus. The disclosure relates further to impact of certain culture factors such as trypsin concentration, pH levels, incubation time, and combinations thereof on the production of viral proteins, particularly haemagglutinin.
The present disclosure provides a self-amplifying RNA (sa-mRNA) comprising an open reading frame encoding a replicase or a non-structural protein 4 (nsP4) and an open reading frame encoding peptide or polypeptide, wherein the open reading frame encoding the peptide or polypeptide is co-expressed with the replicase or nsP4.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
The present disclosure provides a RNA comprising a nucleotide sequence encoding a modified hemagglutinin (HA) protein from an influenza virus, wherein the modified HA protein comprises at least one amino acid substitution or deletion relative to a native HA protein within a HA cleavage site.
The present disclosure provides a RNA comprising a nucleotide sequence encoding a modified hemagglutinin (HA) protein from an influenza virus, wherein the modified HA protein comprises at least one amino acid substitution or deletion relative to a native HA protein within a HA cleavage site.
The use of certain ionizable cationic lipid compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and may be used in the delivery of the therapeutic and in methods of treating certain conditions, or for inducing an immune response.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present disclosure relates to a recombinant virus-like particle (VLP) comprising an antigen for use as a vaccine. In an aspect, the present disclosure relates to a recombinant VLP comprising a capsid fusion protein for use as a vaccine.
The present disclosure relates generally to methods of producing RNA from a DNA template. More particularly, the method of the present disclosure comprises an in vitro transcription method for producing RNA from close-ended DNA (ceDNA) templates.
The present disclosure relates to combination RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of diseases or conditions including respiratory syncytial virus (RSV).
The present disclosure relates to the field of influenza viruses. More particularly, this disclosure relates to donor or seed influenza viruses for use in preparing reassortant influenza viruses for vaccine production.
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07C 229/24 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe carboxyle lié au squelette carboné, p. ex. acide aspartique
C07D 225/02 - Composés hétérocycliques contenant des cycles de plus de sept chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
The use of an ionizable cationic lipid in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, including conventional messenger RNA and self-amplifying messenger RNA, and may be used in the delivery of the therapeutic and in methods of treating certain conditions, or for inducing an immune response.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
63.
VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
The present disclosure relates to lipid nanoparticles for delivery of RNA, the lipid nanoparticle comprising therein a nucleic acid-binding protein or peptide (e.g., a RNA-binding protein or peptide) bound to the RNA, and uses thereof.
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidin or a fragment thereof. The present disclosure also relates to use of the RNAs, polynucleotides or compositions in methods of inducing an immune response in a subject.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present disclosure relates to compositions comprising multiple antigens of interest for use in vaccine formulations. The compositions comprise (a) a polynucleotide (such as an RNA) comprising a nucleotide sequence encoding an antigen and (b) an antigen polypeptide. The compositions can be used in inducing an immune response in a subject and/or in the treatment or prevention of a disease, such as a respiratory viral infection.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA also encodes a chemoattractant, such as chemerin, C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10) or C-X-C motif chemokine ligand 11 (CXCL11). The present disclosure also relates to use of the RNAs and compositions in methods of inducing an immune response in a subject.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
The present disclosure relates to an RNA delivery vehicle comprising lipid nanoparticles comprising the RNA therein, and a RNA-binding protein or peptide coated on the exterior surface of the lipid nanoparticle, and uses thereof.
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
Novel ionizable lipid compounds of Formula I-Het, Formula I and Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
C07D 211/36 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07C 211/32 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons le cycle aromatique à six chaînons faisant partie d'un système cyclique condensé formé par au moins trois cycles contenant des systèmes cycliques dibenzocycloheptane ou dibenzocycloheptène ou leurs dérivés condensés
C07C 219/06 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé les groupes hydroxy étant estérifiés par des acides carboxyliques ayant les groupes carboxyle estérifiants liés à des atomes d'hydrogène ou à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
C07D 211/36 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
C07C 219/06 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé les groupes hydroxy étant estérifiés par des acides carboxyliques ayant les groupes carboxyle estérifiants liés à des atomes d'hydrogène ou à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
C07C 211/32 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons le cycle aromatique à six chaînons faisant partie d'un système cyclique condensé formé par au moins trois cycles contenant des systèmes cycliques dibenzocycloheptane ou dibenzocycloheptène ou leurs dérivés condensés
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
The present disclosure relates to methods for quantifying mRNA capping efficiency. The methods use detectable labels for quantifying the amount of unlabelled mRNA in a sample. The method is applicable to RNA molecules of any sequence and may be used to obtain information on the physical properties of an RNA sample. The present disclosure also relates to kits which can be used for quantifying mRNA capping efficiency.
The present disclosure provides lipid nanoparticles having a sphere like structure, compositions comprising the lipid nanoparticles and methods for delivery of the agents. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
The present disclosure relates compositions of RNA encapsulated in lipid nanoparticles and methods of producing the same The compositions can be used for delivery of mRNA to a subject. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
The present disclosure relates to the field of modified viruses and viral proteins. More particularly, this disclosure relates to modified haemagglutinin proteins, influenza viruses expressing such proteins and methods of making same.
The present disclosure relates to a composition comprising one or more ribonucleic acids (RNAs) encoding virus-like particle (VLP) forming elements of an influenza virus. The present disclosure further provides uses of the composition.
G16H 70/40 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des médicaments, p. ex. leurs effets secondaires ou leur usage prévu
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
The present disclosure relates to multicistronic RNA vaccines and uses thereof. The present disclosure also relates to multicistronic conventional mRNA vaccines and uses thereof. The present disclosure further relates to multicistronic self-replicating RNA vaccines and uses thereof
The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self-replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a Spike (S) protein or a nucleocapsid (N) protein.
The present disclosure provides a method for purifying linear DNA prior to its use to produce RNA, the method comprising ultrafiltering and diafiltering a solution comprising the linear DNA with a membrane having a molecular weight cut off of 200kDa or less. mRNA-based therapies have been shown to be effective in the treatment or prevention of conditions, e.g., in the form of mRNA-based vaccines for the prevention of COVID-19. DNA used in the production of mRNA-based therapies must be sufficiently pure to produce the therapies.
